Is this message not displayed correctly?
Please click here for the online version.
|
|
Dear Sir or Madam, The integration of AI into medicine is rapidly improving diagnostic procedures, treatment plans and healthcare overall. AI algorithms analyze medical data, identify complex patterns and enable faster and more precise diagnoses. They have become indispensable for developing tailored therapies by aligning patient data with medical knowledge. And where is the German capital region in all of this? Right in the midst and at the forefront! We are a partner in the EU project TEF-Health led by Prof. Petra Ritter (Charité) which aims to expedite innovative approaches using artificial intelligence (AI) and robotics in healthcare and to bring them to market. Startups and SMEs can benefit from testing and validation services for their future products ( Call). Berlin is taking a leading role in the " Global Initiative on AI for Health" ( GI-AI4H), where the International Telecommunication Union (ITU), the World Health Organization (WHO), and the World Intellectual Property Organization (WIPO) collaborate to enhance global healthcare through the use of AI. There are also notable entrepreneurial developments. Aignostics, a spin-off of Charité - Universitätsmedizin Berlin, is developing novel digital pathology solutions with "Explainable AI" for pharmaceutical research and diagnostics. Today, we want to introduce an intriguing scientist in this field. Bioinformatician Prof. Dr. Peter N. Robinson has returned to Berlin after years in the US. Read about the new impetus he brings in our interview. Our motto for the next few weeks is: The healthcare industry is a guest in Berlin, and our cluster is a guest in the world. In April, we will welcome the Digital Health Community at the DMEA trade fair and the biotech industry at the German Biotechnology Days. We will represent the Berlin region in Spain at BIO Europe Spring in March, in Switzerland at the Swiss Biotech Day in April, and in the US at the BIO International Convention in June. And what else is worth reading today? We spoke with Peter Seeberger, the leading glycochemist in Europe and director at the Max Planck Institute for Colloids and Interfaces in Potsdam, about current startup plans. In addition, you will find a summary of recent developments in cardiology from the HealthCapital Berlin-Brandenburg. Your Dr. Kai Uwe Bindseil Berlin Partner for Business and Technology |
|
Chemistry on brink of complete transformation Prof. Peter Seeberger, Director at the Max Planck Institute of Colloids and Interfaces in Potsdam, is a renowned expert in the field of glycoscience. He is also a professor at the Freie Universität Berlin and an honorary professor at the University of Potsdam. The chemist can look back on a long academic career that has taken him to some of the most prestigious institutions in his field. He has also been involved in the founding of many companies. We spoke to him about the success of start-ups and the progress of science.. |
|
|
Special topic | Cardiovascular health in Berlin-Brandenburg Whether heart attack, stroke or other heart problems: Cardiovascular diseases are the most common cause of death in Germany. Even though mortality has fallen in recent years thanks to new examination and treatment methods, there is still a lot to be done in research, diagnosis, treatment and prevention. In the Berlin-Brandenburg metropolitan region, a wide range of players are tackling this challenge. |
|
|
Using data for precision medicine Bioinformatician Prof. Dr. Peter N. Robinson is a pioneer in the computer-assisted genome and phenotype analysis of genetic diseases. The Human Phenotype Ontology he developed is now a standard tool used internationally to diagnose gene-related diseases. He has spent a large part of his research and teaching career in Berlin. After several years in the US, he returned to the German capital at the beginning of the year as Alexander von Humboldt Professor of Artificial Intelligence at the Berlin Institute of Health at Charité. We spoke to him about his view of Berlin since his return and about his research. |
|
|
The tip from our relocation experts
Are you looking for funding opportunities in Berlin? Berlin offers attractive funding opportunities for all phases of business development — from start-up to growth financing. Financial incentives range from public loans, guarantees, and equity capital, to direct grants for investment and innovation projects.
|
|
|
Our experts will find the right financing solution and provide you with valuable information on how to apply for funding. We work closely with project sponsors, development banks, and potential financing partners at the state, federal, and EU levels. Together, we discuss the plans for your project, which should ideally already be available in the form of a project description or a business plan. We will check with you which funding and financing instruments come into consideration, establish contacts with relevant players, and provide you with important information for your application. If you need more support with any aspects of funding – talk to us! We look forward to receiving your message. Susan Kaffenberger Berlin Partner for Business and Technology Biotech | Pharma 📧 |
|
|
|
|
Talk im Cube: Female Entrepreneurship - A Panel Discussion
March 14, 2024 | Berlin BioCube
Read more |
|
BIO-Europe Spring® 2024
March 18-20, 2024 | Barcelona, Spain
Read more |
|
DMEA 2024
April 9-11, 2024 | Berlin
|
|
8th BioProScale Symposium 2024
April 9-11, 2024 | Berlin
Read more |
|
German Biotech Days (DBT) 2024
April 16-17, 2024 | Berlin
Read more |
|
Swiss Biotech Day
April 22-23, 2024 | Basel
Read more |
|
BIO International Convention
June 3-6, 2024 | San Diego
Read more |
|
Prague.Bio Conference
September 24, 2024 | Prague
Read more |
|
For more events in the life science region Berlin-Brandenburg click here. |
|
Bayer invests 130 million EUR in new production facility for innovative parenteral products Bayer has added a brand new manufacturing facility to its global supply chain network. The new production plant was inaugurated today at the company’s global pharmaceutical headquarters in Berlin, Germany. The facility features state-of-the-art technology, innovative production, and automated processes. The inauguration of the facility represents a key milestone in realizing Bayer's global manufacturing strategy for pharmaceutical liquid dosage forms, such as injection and infusion solutions.
|
|
|
BIOTRONIK Opens New Asia-Pacific Hub in Singapore
BIOTRONIK announced today the opening of its new Asia Pacific Manufacturing and Research Hub. The 20,000 m² site will serve as the company’s central hub in Asia-Pacific, with hundreds of employees working in manufacturing, quality, research & development (R&D), and sales and marketing. Read more |
|
DiaMonTech closes financing round to finalize development of portable non-invasive glucose monitor
Berlin-based health tech company DiaMonTech has successfully closed a financing round, raising further millions with the Berlin based Moll Family GmbH in the lead.This investment will be instrumental in advancing their pioneering non-invasiveglucose monitoring technology. Read more |
|
Caresyntax Announces Strategic Collaboration with AAICO to Expand AI-based Solutions In Healthcare Caresyntax has entered into a strategic collaboration with The Applied AI Company (AAICO), a leading AI technology company, to distribute novel software and artificial intelligence solutions throughout the UAE, US, and Europe.
|
|
|
Novozymes and Chr. Hansen announce name of future combined company; Novonesis
Read more
|
|
ProBioGen was Granted a New Patent for DirectedLuck® Transposase Technology
Read more
|
|
Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
Read more
|
|
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform
Read more
|
|
Lindis Blood Care announces last patient out in multicenter clinical certification study REMOVE with CATUVAB® to eliminate tumor cells from surgical blood
Read more
|
|
Science and Technology News
|
|
|
Neurological symptoms apparently not a result of SARS-CoV-2 infection of the brain Scientists still are not sure how neurological symptoms arise in COVID-19. Is it because SARS-CoV-2 infects the brain? Or are these symptoms the result of inflammation in the rest of the body? A study by Charité – Universitätsmedizin Berlin has now produced evidence to support the latter theory. It was published today in the journal Nature Neuroscience.
|
|
|
Establishment of the National Center for Tumor Diseases (NCT) Berlin
From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research. Read more |
|
Researchers from the Max Delbrück Center developed a neuromuscular model for drug development
In neuromuscular diseases, neurons and muscle cells stop communicating properly. Researchers led by Mina Gouti can now model this in 2D in a culture dish. Writing about their findings in “Nature Communications”, they say the new model promises to revolutionize high-throughput drug screening studies. Read more |
|
Infection with stomach bacteria may increase risk of Alzheimer's disease - Researchers from Charité and McGill University quantify association between Helicobacter pylori and Alzheimer’s disease
Read more
|
|
Scientists from the Max Delbrück Center describe the role one enzyme plays in removing waste DNA or RNA remains in cells
Read more
|
|
Third ERC Grant for Gaetano Gargiulo from the Max Delbrück Center
Read more
|
|
Gene editing precisely repairs immune cells
Read more
|
|
Pain and touch sensations require Schwann cells
Read more
|
|
Computer-engineered DNA to study cell identities
Read more
|
|
Technology and Cooperation Offers
|
|
|
Sleeping Beauty transposase variants with increased safety due to reduced half-life
Read more |
|
Selective iNOS small molecule inhibitors for the prevention of NO-dependent neuroinflammation
Read more |
|
Next generation allogeneic CAR-NK cell platform for treatment of malignant diseases
Read more |
|
Fiber Membrane Oxygenator with Minimized Priming Volume
Read more |
|
For more news from the cluster healthcare industries click here. |
|
EDITOR | IMPRINT
This newsletter is operated by the cluster healthcare industries
Berlin-Brandenburg HealthCapital.
Berlin Partner for Business and Technology
Fasanenstrasse 85 | 10623 Berlin | Germany
Phone: +49 30 46302-463
Email: info (at) healthcapital.de
Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 B
VAT ID: DE 136629780
CEO: Dr. Stefan Franzke
Chairman of the Supervisory Board: Carsten Jung
© 2024 Berlin Partner for Business and Technology |
|
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology.
|
|
|
You have been forwarded this newsletter and would like to subscribe?
Please click here.You want to unsubscribe from the newsletter (to: unknown@noemail.com)? Please click here.
|
|
|
|
|
